“There is a hue and cry on whether a high dosage of HCQ is toxic. India is administering HCQ in 400 mg doses — two doses on the first day, followed by one per week for three weeks for household contacts, or for seven weeks for healthcare workers. Arthritis patients take 400 mg of the drug daily, and in all these years we have never had a medico-legal case of toxic side effects of HCQ,” said the senior official quoted above.
The Indian government had placed orders for 100 million tablets which have been delivered by two drug majors Ipca and Cadila Healthcare.
Each patient requires either five to nine tablets. Going by that, the stock would last for months as it can cater to about 10 million people.
In fact, in April, sales of the anti-malarial drugs saw an 11 per cent spike in the domestic market.
At one point, Ipca used to make 600 tonnes per annum of chloroquine phosphate and had an 80 per cent share in the global market. However, the demand for the drug has reduced over the years with the particular malaria variant cases coming down.
“We are getting queries from lots of small countries in Latin America and Europe. We are catering to these orders. India also continues to use HCQ. As of now there is no fresh order for HCQ from the government as they have enough stock,” the source added. By May, India had scaled up its HCQ capacity to 300 million tablets per month.
The inexpensive drug that has anti-inflammatory effects (the reason it is used in arthritis) came into limelight after US President Donald Trump
promoted it. Industry insiders feel this may well have also been the drug’s undoing.
“The drug became a political issue and also caused a certain divide in the medical community. On top of that, one country in the world, suddenly shot to fame by supplying the drug to world,” felt a drug firm owner, who did not wish to be named.
Reputed peer reviewed medical journal The Lancet carried a study in May that said HCQ could lead to increased mortality rates and also came with the risk of adverse effects like cardiac arrhythmia. Lancet, however, red-flagged the study last week after several researchers and doctors wrote to it questioning the reliability of the data. Surgisphere, the company that supplied the data allegedly from over 96,000 patients across the globe, came under the scanner.
In fact, another study published in The New England Journal of Medicine (NEJM) that also used the same data was later retracted. This study was on cardiovascular disease, drug therapy and mortality in Covid-19.
The World Health Organisation
(WHO) suspended HCQ trials, which were part of the global Solidarity Trials. Last week it resumed the study after the Lancet study was red flagged.
Meanwhile, there was another study in NEJM that also cast doubts on the use of HCQ. The study on 821 people had limitations though as most participants could not be tested using RT-PCR method. In an editorial in NEJM, Myron S Cohen, an American physician scientist, noted: “Some observational studies have suggested benefits of hydroxychloroquine
for the treatment of Covid-19, whereas other treatment reports have described mixed results.”
Cohen further noted: “Drugs for the prevention of infections must have an excellent safety profile. When hydroxychloroquine
was initially promoted as a possible solution to SARS-CoV-2 infection, the safety of the drug was emphasised. Under closer scrutiny, however, the potential for cardiac toxic effects and overall adverse outcomes have been emphasised, especially in persons with underlying coexisting conditions that increase the risk of severe Covid-19.”
India, meanwhile, has stood by studies conducted by the Indian Council of Medical Research and has recently even expanded the use of HCQ. Whether India will commission more studies to assess the risks and benefits of this drug is to be seen.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.